Arena raising $35M; Dara touts promising pain data; Onyx expands carfilzomib Ph3;

 @FierceBiotech: XTL snags schizophrenia drug in exclusive licensing pact. Article | Follow @FierceBiotech 

 @JohnCFierce: So does anybody else want to stir up buzz about why Eli Lilly Should buy Bristol? Anyone else think that Lechleiter would see value there? | Follow @JohnCFierce 

> Obesity drug developer Arena Pharmaceuticals ($ARNA) is selling 12.15 million shares of its badly battered shares to Deerfield Management in order to raise $35 million, half of which will be used to pay down debt. Arena release

> Raleigh, NC-based Dara BioSciences is reporting promising data for its mid-stage study on a new treatment for cancer pain. Report

> Onyx says it will expand its pivotal trial in Europe for carfilzomib, a closely-watched myeloma drug now in Phase III, to demonstrate added survival time. Article

> Denmark's Lundbeck is launching a Phase I study of a new CNS drug code named AF11167. Story

> J&J quietly shelved plans to mount a trial that would compare its antipsychotic Invega Sustenna with oral treatments. The move was triggered by "an internal reconsideration of priorities of the product portfolio." Report

> HighRes Biosolutions received a $125,000 tax incentive award from the Massachusetts Life Science Centre in exchange for its pledge to create 10 new jobs. Item

> Cellceutix is touting a confidential disclosure agreement it signed on its autism drug candidate. Story

Pharma News

@FiercePharma: With $120K price tag, Yervoy hailed as potential blockbuster. News | Follow @FiercePharma

> Gout medicine Colcrys' pricing under scrutiny. Report

> Novartis CEO: iPad saves time, keeps reps honest. Article

> More evidence links Lipitor with diabetes. Item

Biotech Research News

> Asthma drug takes care of tricky Alzheimer's enzyme. Story

> Researchers: Early MS nerve cell damage can be reversed. News

> Nicotine: A guilty arty in diabetes complications. Report

> Nanoparticles help detect circulating tumor cells. Item

> Researchers see future in stem cell therapy for macular degeneration. Article

> New laser technique may make drug discovery easier. Item

Manufacturing News

> P&G/Teva manufacturing savvy threatens J&J. Article

> Particles, odors again drive recalls, but origins differ. Report

> Gray market thriving on drug shortages. Story

And Finally.... A group of researchers at Georgetown University Medical Center have taken what they call a "significant step" in combining AMD research with another important study area--stem cell therapy. Story